Alliance Pharma (LSE:APH) Interest Expense : £-7.4 Mil (TTM As of Jun. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Alliance Pharma's interest expense for the six months ended in Jun. 2023 was £ -4.3 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2023 was £-7.4 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Alliance Pharma's Operating Income for the six months ended in Jun. 2023 was £ 13.2 Mil. Alliance Pharma's Interest Expense for the six months ended in Jun. 2023 was £ -4.3 Mil. Alliance Pharma's Interest Coverage for the quarter that ended in Jun. 2023 was 3.08. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Alliance Pharma Interest Expense Historical Data

The historical data trend for Alliance Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma Interest Expense Chart

Alliance Pharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

-3.04

-3.29

-2.08

-3.01

-4.79

Alliance Pharma Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Interest Expense	Get a 7-Day Free Trial															-1.46	-1.55	-1.71	-3.08	-4.28

Alliance Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-7.4 Mil.

Alliance Pharma (LSE:APH) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Alliance Pharma's Interest Expense for the six months ended in Jun. 2023 was £-4.3 Mil. Its Operating Income for the six months ended in Jun. 2023 was £13.2 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2023 was £123.7 Mil.

Alliance Pharma's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Jun. 2023 )	/	Interest Expense (Q: Jun. 2023 )
	=	-1	*	13.195	/	-4.279
	=	3.08

The higher the ratio, the stronger the company's financial strength is.

Alliance Pharma (LSE:APH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

DVL:Germany

Address

Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB

Website

https://www.alliancepharmaceuticals.com

Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).